EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework

Alin Ciubotaru iD, Cristina Grosu, Daniel Alexa, Laura-Elena Cucu iD, Thomas Gabriel Schreiner iD, Cătălina Elena Bistriceanu, Alexandra Maştaleru iD, Doina Azoicāi, Albert Vamanu, Alexandru Patrascu, Dan Iulian Cuciureanu, Emilian Bogdan Ignat iD

Nutrients · 2026

DOI: 10.3390/nu18101538 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2026. Verfasst von Alin Ciubotaru und 11 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Thioctic Acid, Thiamine, Diabetic Neuropathies, Antioxidants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetic peripheral neuropathy (DPN) affects up to 50% of diabetes patients and is driven by hyperglycemia-induced oxidative stress, mitochondrial dysfunction, polyol pathway activation, advanced glycation end-product formation, and inflammation. Current management is largely symptomatic, prompting interest in metabolic/nutritional therapies. This review critically evaluates the mechanistic rationale and clinical evidence for alpha-lipoic acid (ALA) and benfotiamine as adjunctive treatments for DPN.

Methods

A structured narrative review of PubMed/MEDLINE was conducted using predefined keywords for DPN, oxidative stress, metabolic therapy, and thiamine derivatives. Randomized controlled trials, clinical studies, systematic reviews, and relevant experimental studies were included. Evidence was synthesized qualitatively with emphasis on mechanistic plausibility, clinical efficacy, intervention duration, and methodological rigor.

Results

ALA consistently improves short-term symptoms across multiple randomized trials. The long-term NATHAN 1 trial reported a marginal, borderline significant effect on the primary composite endpoint (NIS-LL, p = 0.05) without significant improvements in nerve conduction studies; therefore, evidence for functional stabilization is very limited and inconclusive. ALA’s effects are attributed to antioxidant activity, mitochondrial protection, and improved microvascular function. Benfotiamine has a strong biochemical rationale (transketolase activation, diversion of glycolytic intermediates from damaging pathways), but clinical evidence remains limited to short-duration, symptom-based studies, with no large-scale, long-term trials published.

Conclusions

Both agents target key pathways in DPN pathogenesis. ALA is the most established adjunctive metabolic therapy for symptomatic DPN, although no study has demonstrated structural nerve regeneration or a definitive disease-modifying effect. Benfotiamine is biologically plausible but requires further validation in long-term randomized trials with structural and biomarker-based endpoints. Outside of documented thiamine deficiency, its routine use cannot be recommended based on current evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thioctic AcidThiamineDiabetic NeuropathiesAntioxidantsHumansOxidative StressRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

advanced glycation end productsalpha-lipoic acidbenfotiaminediabetic peripheral neuropathymetabolic therapynutritional interventionoxidative stresstransketolase

Substanzen

Thioctic AcidThiaminebenphothiamineAntioxidants

Autor:innen und Institutionen

  • Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Basic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
  • Apollonia University, 700511 Iasi, Romania.

ORCID-Profile: Alin Ciubotaru, Laura-Elena Cucu, Thomas Gabriel Schreiner, Alexandra Maştaleru, Emilian Bogdan Ignat

Zitieren

APA

Ciubotaru, A., Grosu, C., Alexa, D., Cucu, L. E., Schreiner, T. G., Bistriceanu, C. E., Maştaleru, A., Azoicāi, D., Vamanu, A., Patrascu, A., Cuciureanu, D. I., & Ignat, E. B. (2026). Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. Nutrients. https://doi.org/10.3390/nu18101538

Vancouver

Ciubotaru A, Grosu C, Alexa D, Cucu LE, Schreiner TG, Bistriceanu CE, et al. Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. Nutrients. 2026. doi:10.3390/nu18101538

BibTeX
@article{Ciubotaru2026,
  author = {Ciubotaru, Alin and Grosu, Cristina and Alexa, Daniel and Cucu, Laura-Elena and Schreiner, Thomas Gabriel and Bistriceanu, Cătălina Elena and Maştaleru, Alexandra and Azoicāi, Doina and Vamanu, Albert and Patrascu, Alexandru and Cuciureanu, Dan Iulian and Ignat, Emilian Bogdan},
  title = {Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18101538}
}
Kostenlos starten →